Literature DB >> 17925543

Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.

Karen H Lu1, John O Schorge, Kerry J Rodabaugh, Molly S Daniels, Charlotte C Sun, Pamela T Soliman, Kristin G White, Rajyalakshmi Luthra, David M Gershenson, Russell R Broaddus.   

Abstract

PURPOSE: Age younger than 50 years at the time of colon cancer diagnosis is often used as a screening criterion for Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome). The purpose of this study was to determine the prevalence of MLH1, MSH2, and MSH6 mutations in an unselected cohort of women diagnosed with endometrial cancer at age younger than 50 years.
METHODS: A prospective, multicenter study was performed at three institutions. After written consent was obtained, germline mutation testing by full sequencing and large deletion analysis of the MLH1, MSH2, and MSH6 genes was performed. Tumor studies included immunohistochemistry of MLH1, MSH2, and MSH6; microsatellite instability analysis; and hypermethylation of the MLH1 promoter.
RESULTS: Of the 100 women, nine (9%; 95% CI, 4.2 to 16.4) carried a deleterious germline mutation: seven women with mutations in MSH2, one woman with a mutation in MLH1, and one woman with a mutation in MSH6. Two additional women had molecular studies consistent with the diagnosis of Lynch syndrome. The mean body mass index (BMI) for the entire cohort was 34.4, which is significantly higher than 29.2, the mean BMI for the mutation carriers. Predictors of finding a germline mutation included having a first-degree relative with a Lynch syndrome-associated cancer, endometrial tumor with loss of MSH2 expression, tumors with high microsatellite instability, and lower BMI.
CONCLUSION: In this prospective study of endometrial cancer patients younger than age 50 years, 9% were found to carry germline Lynch syndrome-associated mutations. In addition to young age of onset, family history, BMI, and molecular tumor studies can improve the likelihood of identifying a Lynch syndrome-associated germline mutation in MLH1, MSH2, and MSH6.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925543     DOI: 10.1200/JCO.2007.10.8597

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  66 in total

Review 1.  The inherited genetics of ovarian and endometrial cancer.

Authors:  Simon A Gayther; Paul D P Pharoah
Journal:  Curr Opin Genet Dev       Date:  2010-04-24       Impact factor: 5.578

2.  Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.

Authors:  Andreas Obermair; Danny R Youlden; Joanne P Young; Noralane M Lindor; John A Baron; Polly Newcomb; Susan Parry; John L Hopper; Robert Haile; Mark A Jenkins
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

Review 3.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

4.  Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers.

Authors:  Aung Ko Win; James G Dowty; Yoland C Antill; Dallas R English; John A Baron; Joanne P Young; Graham G Giles; Melissa C Southey; Ingrid Winship; Lara Lipton; Susan Parry; Stephen N Thibodeau; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Noralane M Lindor; Polly A Newcomb; John L Hopper; Mark A Jenkins
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

5.  Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.

Authors:  A S McCampbell; M L Mittelstadt; R Dere; S Kim; L Zhou; B Djordjevic; P T Soliman; Q Zhang; C Wei; S D Hursting; K H Lu; R R Broaddus; C L Walker
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

6.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Authors:  Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 7.  Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.

Authors:  Larissa A Meyer; Russell R Broaddus; Karen H Lu
Journal:  Cancer Control       Date:  2009-01       Impact factor: 3.302

8.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

9.  Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.

Authors:  Seyedeh Ghazaleh Dashti; Rowena Chau; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Ingrid M Winship; Julie Arnold; Dennis J Ahnen; Robert W Haile; Graham Casey; Steven Gallinger; Stephen N Thibodeau; Noralane M Lindor; Loïc Le Marchand; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

10.  Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.

Authors:  Kari L Ring; Amanda S Bruegl; Brian A Allen; Eric P Elkin; Nanda Singh; Anne-Renee Hartman; Molly S Daniels; Russell R Broaddus
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.